RxDoctor Payments Data

Timothy Medcalf, MD

Cardiovascular Disease · Ada, OKNPI 1548221443

Payments from drug & device makers

$777in general payments, 2019–2025

Across 54 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$605
  • AstraZeneca$55
  • Merck$35
  • Pfizer$34
  • Boston Scientific$17
  • Novartis$17
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$777 in reported general payments places this provider in the 25th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$90,058
Medicare patients
2,139
Services billed
4,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban427$330,504
EliquisApixaban376$295,337
FarxigaDapagliflozin Propanediol316$252,621
EntrestoSacubitril/Valsartan35$38,370
Ranolazine ErRanolazine147$7,262
VascepaIcosapent Ethyl16$6,653
VerquvoVericiguat11$6,576
Pravastatin Sodium394$3,128
AliskirenAliskiren Hemifumarate20$2,798
ClopidogrelClopidogrel Bisulfate236$2,752
Torsemide235$2,583
Rosuvastatin Calcium156$2,333
Eplerenone27$2,214
Omega-3 Acid Ethyl Esters30$2,184
Carvedilol317$2,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$605$330,504427 claims
PfizerEliquis$34$295,337376 claims
AstraZenecaFarxiga$55$252,621316 claims
NovartisEntresto$17$38,37035 claims
MerckVerquvo$35$6,57611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →